> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Votrient Not Withdrawn Due to Safety/Efficacy: FDA
- URL: https://www.fdaweb.com/votrient-not-withdrawn-due-to-safety-efficacy-fda/
- Published: 2021-08-04T12:00:00.000Z
- Updated: 2026-09-14T17:09:12.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149861

*Federal Register* notice: FDA has determined that Novartis’ Votrient (pazopanib hydrochloride) tablets, 400 mg, were not withdrawn from sale due to safety or effectiveness reasons. The determination will allow FDA to approve ANDAs that reference the product if all other legal and regulatory requirements are met. Votrient is a kinase inhibitor indicated for treating patients with advanced renal cell carcinoma. To view the notice, click [here](https://public-inspection.federalregister.gov/2021-16692.pdf?ref=fdaweb.com).